Association between genetic variants in glutathione peroxidase 1 gene and risk of prostate cancer: a meta-analysis

To examine the association between glutathione peroxidase 1 (GPx1) gene Pro198Leu polymorphism with the development and progression of prostate cancer. A comprehensive search was conducted to identify all case–control studies of GPx1 polymorphisms and prostate cancer. Statistical analysis was performed with the software program Stata, version 11.0, and Review Manage, version 4.2. A total of 7 eligible studies relating the GPx1 polymorphism to the risk of prostate cancer were identified. The results indicated no significant association between GPx1 polymorphisms and prostate cancer susceptibility in the dominant model (random effects OR 0.75, 95 % CI 0.48–1.18), recessive model (random effects OR 0.47, 95 % CI 0.22–1.01) and co-dominant genetic model (random effects OR 0.72, 95 % CI 0.43–1.21). For the analysis of GPx1 polymorphism and progression of prostate cancer, no significant association were found in the dominant model (fixed effects OR 1.20, 95 % CI 0.95–1.52), recessive model (fixed effects OR 0.69, 95 % CI 0.48–1.00) and co-dominant genetic model (fixed effects OR 0.95, 95 % CI 0.79–1.15). Egger’s test showed that publication bias was not present in all the comparisons.